Akebia Therapeutics Analyst Price Targets

Wall Street analyst price targets and consensus rating for Akebia Therapeutics (AKBA).

Price Target Range — 11 Quarters

Analyst Consensus — 5 Analysts

4Buy

1Hold

Consensus RatingBuy# Analysts5Avg. Consensus PT$5Upside to Avg. PT+385.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 7, 2026	Leerink Partners	Roanna Ruiz	Downgrade	Outperform→Market Perform	$1
Jul 1, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Apr 7, 2026	BTIG	Julian Harrison	Maintained	Buy	$4
Feb 25, 2026	BTIG	Julian Harrison	PT Cut	Buy	$5→$4
Feb 6, 2026	Piper Sandler	Allison Bratzel	PT Cut	Overweight	$6→$4
Feb 6, 2026	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Dec 2, 2025	BTIG	Julian Harrison	Maintained	Buy	$5
Dec 2, 2025	HC Wainwright & Co.	Matthew Caufield	Maintained	Buy	$6
Oct 30, 2025	HC Wainwright & Co.	Matthew Caufield	PT Cut	Buy	$8→$6
Oct 29, 2025	BTIG	Julian Harrison	PT Cut	Buy	$10→$5
Jun 4, 2025	HC Wainwright & Co.	Matthew Caufield	Assumes	Buy	$8
Apr 28, 2025	Leerink Partners	Roanna Ruiz	Initiate	Outperform	$7
Apr 4, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Apr 1, 2025	Jefferies	Roger Song	Initiate	Buy	$6
Mar 14, 2025	Piper Sandler	Allison Bratzel	PT Raise	Overweight	$4→$6
Mar 14, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Jan 23, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Jan 14, 2025	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Oct 23, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8
Oct 10, 2024	HC Wainwright & Co.	Ed Arce	Maintained	Buy	$8